Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.47 |
| ▸ | BACE1 | P56817 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | P2RX7 | Q99572 | 6/20 | 0.46 |
| ▸ | PREP | P48147 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3049200 | 0.96 | SIGMAR1 (0.60) | SIGMAR1MEN1KMT2AHTTGPR119 | |
| SCHEMBL18751212 | 0.96 | SIGMAR1 (0.60) | SIGMAR1MEN1KMT2AHTTGPR119 | |
| SCHEMBL4075221 | 0.93 | SIGMAR1 (0.57) | SIGMAR1MEN1KMT2AHTTGPR119 | |
| SCHEMBL14691386 | 0.87 | SIGMAR1 (0.66) | SIGMAR1MEN1KMT2AHTTALDH1A1 | |
| SCHEMBL3040666 | 0.85 | KDM4E (0.62) | HTTGPR119ALDH1A1 | |
| SCHEMBL11263011 | 0.84 | PREP (0.59) | SIGMAR1MEN1KMT2AHTTALDH1A1 | |
| SCHEMBL7159251 | 0.84 | PREP (0.59) | SIGMAR1MEN1KMT2AHTTALDH1A1 | |
| SCHEMBL3045888 | 0.84 | TPSAB1 (0.64) | MEN1KMT2AHTTGPR119ALDH1A1 | |
| SCHEMBL2586953 | 0.83 | L3MBTL1 (0.61) | ALDH1A1PREPL3MBTL1 | |
| SCHEMBL17294006 | 0.83 | SIGMAR1 (0.64) | SIGMAR1MEN1KMT2AHTTPREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2057116-B1 | NEW PHENYLSULFAMOYL BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT (HU) | 2013-02-13 | — | — | EP | disclosed |
| US-20130029991-A1 | New Phenylsulfamoyl Benzamide Derivatives as Bradykinin Antagonists | BEKE GYULA (HU) | 2013-01-31 | — | — | US | disclosed |
| US-20120295910-A1 | New Phenylsulfamoyl Benzamide Derivatives as Bradykinin Antagonists | BEKE GYULA (HU) | 2012-11-22 | — | — | US | disclosed |
| US-20100105686-A1 | PHENYLSULFAMOYL BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT. (HU) | 2010-04-29 | — | — | US | disclosed |
| EP-2057116-A1 | NEW PHENYLSULFAMOYL BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | Richter Gedeon NYRT (HU) | 2009-05-13 | — | — | EP | disclosed |
| WO-2008050167-A1 | NEW PHENYLSULFAMOYL BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT. (HU) | 2008-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295910-A1 | New Phenylsulfamoyl Benzamide Derivatives as Bradykinin Antagonists | BDKRB1, BDKRB2, HRH4 | SIGMAR1 289/4885MEN1 2640/4885KMT2A 2478/4885 |
| US-20130029991-A1 | New Phenylsulfamoyl Benzamide Derivatives as Bradykinin Antagonists | BDKRB1, BDKRB2, HRH4 | SIGMAR1 329/4885MEN1 2895/4885KMT2A 2406/4885 |
| US-20100105686-A1 | PHENYLSULFAMOYL BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | BDKRB1, BDKRB2, HRH1 | SIGMAR1 314/4885MEN1 2650/4885KMT2A 2464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.